top of page
Backgrounds.jpg
Statesman-Examiner Logo 2025 with Shadow.png

Loading...

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Myriad Genetics, Inc. - Common Stock (NQ:MYGN)

6.070 -0.130 (-2.10%)
Streaming Delayed Price Updated: 12:02 PM EST, Jan 14, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Myriad Genetics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
News headline image
Myriad Genetics Announces Select Preliminary Fourth Quarter and Full Year 2025 Financial Results and Introduces Full Year 2026 Financial Guidance
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Myriad Genetics to Present at 44th Annual J.P. Morgan Healthcare Conference
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Myriad Genetics to Present 8 Abstracts about MRD and Other Studies at 2025 San Antonio Breast Cancer Symposium
New data will be presented about Precise® Molecular Residual Disease (MRD) Test and MyRisk® Hereditary Cancer Test 
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Clairity, Myriad Genetics, and MagView Launch the First Integrated AI and Genetic Risk Platform for Personalized Breast Health
Actionable offering helps enable earlier, more personalized breast cancer interventions 
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Myriad Genetics to Participate in Upcoming Investor Healthcare Conferences
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Myriad Genetics Adds 15 Clinically Actionable Genes to MyRisk® Hereditary Cancer Test to Support Evolving Clinical Needs
100% of genes strongly recommended by national oncology guidelines are included in the MyRisk Test 
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Myriad Genetics to Highlight Genetic Testing Advancements at 2025 National Society of Genetic Counselors Annual Conference
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Myriad Genetics Reports Third Quarter 2025 Financial Results; Reiterates 2025 Financial Guidance Following Continued Solid Execution
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
New Post-Hoc Analysis Shows Patients Whose Clinicians Had Access to GeneSight Results for Depression Treatment Are More Likely to Feel Better Sooner
Faster initial remission and response, persistent benefit over six months 
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Myriad Genetics to Release Third Quarter 2025 Financial Results on November 3, 2025
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Myriad Genetics Adds F8, FXN Genes to Foresight Universal Plus Panel
The Foresight® Carrier Screen includes all conditions recommended by the American College of Medical Genetics and Genomics recommendations 
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Breast Cancer Awareness Month: Patient and Clinician Share Insights on how to tackle the fear of cancer screenings on YourUpdateTV
From D S Simon
Via GlobeNewswire
News headline image
Myriad Genetics and SOPHiA GENETICS to Develop an Innovative Companion Diagnostic Offering in Liquid Biopsy
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Myriad Genetics Announces Precise MRD Clinical Data Published in The Lancet Oncology
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
New Meta-Analysis Demonstrates that Access to the GeneSight Test Can Significantly Improve Response and Remission Rates for Patients with Depression
Results published in the Journal of Clinical Psychopharmacology 
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Myriad Genetics to Participate in Upcoming Investor Healthcare Conferences
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
ANGLE Announces Collaboration with Myriad Genetics
Via ACCESS Newswire
News headline image
Myriad Genetics Appoints Ben Wheeler Chief Financial Officer
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
New Myriad Genetics Survey Uncovers Women Fear Screenings—But Feel Reassured by the Results
Cancer Risk Survey shows that more than half of women at high-risk for hereditary cancer would feel "empowered" by more advanced screening like genetic testing 
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Myriad Genetics Reports Second Quarter 2025 Financial Results; Raises 2025 Revenue Guidance Following Positive Business Momentum
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Myriad Genetics Announces New $200 Million Credit Facility
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Myriad Genetics to Release Second Quarter 2025 Financial Results on August 5, 2025
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Myriad Genetics Earns 2025 Great Place To Work Certification™
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Myriad Genetics Announces Early Access to the FirstGene Multiple Prenatal Screen
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Myriad Genetics Shares New Clinical Data Demonstrating Sensitivity of Precise MRD Across Multiple Cancer Types
MONSTAR-SCREEN-3 study showed 100% detection of circulating tumor DNA (ctDNA) at baseline timepoint, and 60% of patients testing positive one month after surgery had tumor fractions only detectable via... 
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Myriad Genetics Highlights New Research Advancements and Oncology Innovations at 2025 ASCO Annual Meeting
Two Molecular Residual Disease (MRD) studies highlighting clinical data among seven new studies to be shared by Myriad and collaborators 
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Updated: Myriad Genetics to Participate in Two Upcoming Investor Healthcare Conferences
Correction: Time of BofA Conference 
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Securities Fraud Investigation Into Myriad Genetics, Inc. (MYGN) Announced – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm
From Glancy Prongay & Murray LLP
Via Business Wire
News headline image
Myriad Genetics, Inc. (MYGN) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
From Law Offices of Howard G. Smith
Via Business Wire
News headline image
Securities Fraud Investigation Into Myriad Genetics, Inc. (MYGN) Announced – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
From The Law Offices of Frank R. Cruz
Via Business Wire
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
bottom of page